1-p-chlorobenzyl-1H-indazole-3-carboxylic acid is a synthetic organic compound with the chemical formula C15H11ClN2O2.
Here's a breakdown of its structure and importance in research:
**Structure:**
* **Indazole core:** The molecule has a core structure called indazole, which is a bicyclic aromatic ring system containing a benzene ring fused to a pyrazole ring.
* **Substitution:** At the 1 position of the indazole ring, there's a p-chlorobenzyl group, meaning a benzyl group (CH2-Ph) with a chlorine atom attached at the para (opposite) position on the benzene ring.
* **Carboxylic acid:** The molecule has a carboxylic acid (-COOH) group attached at the 3 position of the indazole ring.
**Research Importance:**
The importance of 1-p-chlorobenzyl-1H-indazole-3-carboxylic acid lies in its potential pharmacological properties and its role as a building block for other research chemicals.
Here are some potential areas of research interest:
* **Drug discovery:** The compound's structure suggests potential for biological activity. It might act as a:
* **Ligand:** It could bind to specific receptors or proteins, triggering biological effects.
* **Enzyme inhibitor:** It could block the activity of certain enzymes, potentially useful in treating various diseases.
* **Synthesis and medicinal chemistry:** The compound can serve as an intermediate in the synthesis of other more complex molecules with potential medicinal value. Researchers might modify the structure to optimize its properties and explore its therapeutic potential.
* **Material science:** The compound might exhibit unique properties like fluorescence or luminescence, making it useful in materials science applications.
**Important Note:**
It's crucial to understand that while the molecule's structure suggests potential for research, it is not necessarily a confirmed drug or a material with proven applications. Further research and development are needed to determine its true biological activity and potential applications.
**To further explore the importance of this compound:**
* **Search online databases:** Use databases like PubChem or SciFinder to find research papers or patents related to this compound.
* **Contact research groups:** Reach out to research groups working in the field of medicinal chemistry or drug discovery to inquire about their research related to this compound.
1-p-chlorobenzyl-1H-indazole-3-carboxylic acid: RN given refers to cpd with isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 100493 |
CHEMBL ID | 3276570 |
CHEBI ID | 93180 |
SCHEMBL ID | 3500587 |
MeSH ID | M0051139 |
Synonym |
---|
50264-86-3 |
nsc309701 |
1h-indazole-3-carboxylic acid, 1-[(4-chlorophenyl)methyl]- |
nsc-309701 |
mls003115871 , |
1-p-chlorobenzyl-1h-indazole-3-carboxylic acid |
1h-indazole-3-carboxylic acid, 1-((4-chlorophenyl)methyl)- |
nsc 309701 |
af 1312/ts |
1-((4-chlorophenyl)methyl)-1h-indazole-3-carboxylic acid |
af 1312ts |
1-(4-chlorobenzyl)-1h-indazole-3-carboxylic acid |
brn 0888596 |
OPREA1_458144 |
af-1312/ts |
smr001831437 |
BRD-K67484673-001-01-5 |
1-[(4-chlorophenyl)methyl]indazole-3-carboxylic acid |
BRD-K67484673-001-02-3 |
MLS003271339 |
AKOS012406886 |
CHEMBL3276570 |
SCHEMBL3500587 |
DTXSID70198266 |
CHEBI:93180 |
Q27164901 |
1-[(4-chlorophenyl)methyl]-3-indazolecarboxylic acid |
1-(p-chlorobenzyl)indazolyl-3-carboxylic acid |
E77693 |
AS-83009 |
1-[(4-chlorophenyl)methyl]-1h-indazole-3-carboxylic acid |
Excerpt | Reference | Relevance |
---|---|---|
" AF 1312/TS (1-(4-chlorobenzyl)-1H-indazole-3-carboxylic acid) when administered from day 6 to day 15 of pregnancy produced embryolethality with an LD50 of 145 mg/kg." | ( The embryotoxicity of a new class of antispermatogenic agents: the 3-indazole-carboxylic acids. Campana, A; De Martino, C; Scorza Barcellona, P; Silvestrini, B, 1982) | 0.26 |
Class | Description |
---|---|
indazoles | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID1150559 | Antispermatogenic activity in po dosed Long-Evans rat assessed as reduction of testes weight administered as single dose measured after 5 days | 1976 | Journal of medicinal chemistry, Jun, Volume: 19, Issue:6 | 1-Halobenzyl-1H-indazole-3-carboxylic acids. A new class of antispermatogenic agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 6 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (10.00) | 29.6817 |
2010's | 2 (20.00) | 24.3611 |
2020's | 1 (10.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.74) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |